Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting… Read more










































Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the SGLT2 protein in the proximal renal tubules, this medication reduces glucose reabsorption and promotes urinary glucose excretion. The comprehensive range of Canagliflozin reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites such as glucuronides, and stable isotope labelled compounds, is essential for rigorous analytical support. These materials are utilized by pharmaceutical laboratories for accurate impurity profiling, method development, and validation of analytical procedures. By providing reliable benchmarks for identification and quantification, these standards facilitate consistent quality control and ensure compliance with regulatory guidelines throughout the drug development and manufacturing lifecycle.